Achilles Therapeutics plc (id:8440 ACHL)
1.06 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/22/2024 12:57:55 PM)
Exchange open, closes in 3 hours 2 minutes
About Achilles Therapeutics plc
Market Capitalization 45.69M
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
| Headquarters (address) |
245 Hammersmith Road London W6 8PW United Kingdom |
| Phone | 44 20 8154 4600 |
| Website | https://www.achillestx.com |
| Employees | 204 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ACHL |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.680 - 1.76 |
| Market Capitalization | 45.69M |
| P/E trailing | -0.615 |
| P/E forward | -0.572 |
| Price/Book | 0.381 |
| Beta | 1.34 |
| EPS | -1.59 |
| EPS United Kingdom (ID:3, base:637) | 0.430 |